



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 307/32, A61K 31/00, A23L 1/30	A1	(11) International Publication Number: WO 00/59946 (43) International Publication Date: 12 October 2000 (12.10.00)
(21) International Application Number: PCT/FI00/00181 (22) International Filing Date: 9 March 2000 (09.03.00) (30) Priority Data: 09/281,094 30 March 1999 (30.03.99) US (71) Applicant (for all designated States except US): HORMOS NUTRACEUTICAL OY LTD [FI/FI]; Tykistökatu 6 A, FIN-20520 Turku (FI). (72) Inventors; and (75) Inventors/Applicants (for US only): AHOTUPA, Markku [FI/FI]; Karjakuja 82, FIN-20540 Turku (FI). ECKERMAN, Christer [FI/FI]; Itäharjuntatu 12, FIN-20540 Turku (FI). KANGAS, Lauri [FI/FI]; Pasantie 3 B, FIN-21280 Raisio (FI). MÄKELÄ, Sari [FI/FI]; Metsäpirtinkatu 4, FIN-20740 Turku (FI). SAARINEN, Niina [FI/FI]; Löytänänkatu 2 C 14, FIN-20540 Turku (FI). SANTTI, Risto [FI/FI]; Mannerheiminkatu 23, FIN-21100 Naantali (FI). WÄRRI, Anni [FI/FI]; Juhaninkuja 2 as 2, FIN-21420 Lieto (FI). (74) Agent: TURUN PATENTTITOIMISTO OY; P.O. Box 99, FIN-20521 Turku (FI).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: HYDROXYMATAIRESINOL IN CANCER PREVENTION (57) Abstract <p>This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

HYDROXYMATAIRESINOL IN CANCER PREVENTION

5

FIELD OF THE INVENTION

This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.

BACKGROUND OF THE INVENTION


The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

Lignans are defined as a class of phenolic compounds possessing a 2,3-dibenzylbutane skeleton. They are formed by coupling of monomeric units called precursors such as cinnamic acid, caffeic, ferulic, coumaric, and gallic acids (Ayres and Loike, 1990). Lignans are widely distributed in plants. They can be found in different parts (roots, leaves, stem, seeds, fruits) but mainly in small amounts. In many sources (seeds, fruits) lignans are found as glycosidic conjugates associated with fiber component of plants. The most common dietary sources of mammalian lignan precursors are unrefined

grain products. The highest concentrations in edible plants have been found in flaxseed, followed by unrefined grain products, particularly rye. Mammalian lignan production from different plant food are given in Table 1.

5 Considerable amounts of lignans are also found in coniferous trees. The type of lignans differs in different species and the amounts of lignans vary in different parts of the trees. The typical lignans in heart wood of spruce (*Picea abies*) are hydroxymatairesinol (HMR), α -conidendrin, conidendrinic acid, matairesinol, isolariciresinol, secoisolariciresinol, liovile, picearesinol, lariciresinol and pinoresinol
 10 (Ekman 1979). The far most abundant single component of lignans in spruce is HMR, about 60 per cent of total lignans, which occurs mainly in unconjugated free form. Lignan concentration in thick roots is 2-3 per cent. Abundance of lignans occur in the heart wood of branches (5 - 10 per cent) and twists and especially in the knots, where the amount of lignans may be higher than 10 per cent (Ekman, 1976 and 1979). These
 15 concentrations are about hundred-fold compared to ground flax powder known as lignan-rich material.

The chemical structure of hydroxymatairesinol is



Lignans can be isolated e.g. from compression-wood fiber. These fibers originate from compression wood of stems and knots (oversize chip fraction) worsen the quality of paper (Ekman, 1976).

- 5 Plant lignans such as matairesinol and secoisolariciresinol, are converted by gut microflora to mammalian lignans, enterolactone and enterodiol, correspondingly (Axelson et al. 1982). They undergo an enterohepatic circulation and are excreted in the urine as glucuronide conjugates (Axelson and Setchell, 1981). As an experimental evidence for the chemopreventive actions of lignans, supplementation of a high-fat diet with lignan-rich flaxseed flour (5% or 10%) or flaxseed lignans (secoisolariciresinol-diglycoside, SDG) prevented the development of antiestrogen-sensitive DMBA-induced breast cancer in the rat (Serraino and Thompson 1991 and 1992; Thompson et al. 1996a and 1996b). They reduced the epithelial cell proliferation, nuclear aberrations, the growth of tumors, and the development of new tumors. High lignan intake may also protect against experimental prostate and colon cancers. Dietary rye (containing lignans), prevented at early stages the growth of transplanted Dunning R3327 prostatic adenocarcinomas in rats (Zhang et al. 1997; Landström et al. 1998). The percentage of animals bearing palpable tumors, the tumor volume, and the growth rate were significantly lower. Further, flaxseed or SDG supplementation inhibited the formation of chemically induced aberrant crypts in rat colon (Serraino and Thompson 1992; Jenab and Thompson 1996). The antitumor action may therefore be due to weak estrogen-antiestrogen-like properties and/or other mechanisms, which are not well understood.
- 25 Urinary excretion and serum concentrations of enterolactone are low in women diagnosed with breast cancer (Ingram et al. 1997; Hultén et al. 1998) suggesting that lignans are chemopreventive. Mammalian lignans (enterolactone and enterodiol) have been hypothesized to modulate hormone-related cancers, such as breast cancer, because of their structural similarities to the estrogens. Enterolactone had weak estrogenic potency in MCF-7 cells (Mousavi and Adlercreutz 1992), but had no
- 30

estrogenic response in mouse uterine weight (Setchell et al. 1981). As a sign of estrogen-like activity, SDG feeding during pregnancy and lactation to rats increased the uterine weight at weaning but the effect was not evident at later stages (Tou et al. 1998). Possible antitumor effects have also been associated with their antiestrogenic
5 actions (Waters and Knowler, 1982). The inhibition of aromatase by mammalian lignan, enterolactone, would suggest a mechanism by which consumption of lignan-rich plant food might contribute to reduction of estrogen-dependent diseases, such as breast cancer (Adlercreutz et al. 1993, Wang et al. 1994). The potential antioxidant activity of lignans could also represent a mechanism associated with the preventive
10 action of lignans in the development of cancers. Further, mammalian lignans have shown to inhibit the conversion of testosterone to 5 α -dihydrotestosterone (DHT), the potent intracellular androgen, at the concentrations which are achievable in humans (Evans et al. 1995). The reduction in DHT concentration would modify the risk of prostate cancer (PC) and benign prostatic hyperplasia (BPH).

15

It is possible that lignans as precursors of enterolactone could also alleviate lower urinary tract symptoms (LUTS) and gynecomastia. On the basis of the results obtained in the animal model, we have suggested that estrogens play an essential role in the development of the muscular dysfunction involved in urethral dyssynergia seen as
20 bladder neck dyssynergia or external sphincter pseudodyssynergia (Streng et al. unpublished observations). Such neuromuscular changes are at least partially reversed by an aromatase inhibitor (MPV-2213ad) indicating the role of estrogens. Further, gynecomastia, which is induced by exposure to estrogens or in the presence of increased ratio of estrogen to androgens. Gynecomastia can be successfully treated
25 with an aromatase inhibitor. The capability of lignans to inhibit 5 α -reductase and/ or aromatase combined with their potential antioxidant activity may represent mechanisms associated with the preventive action of lignans in the development of hormone-related diseases in male organism.

30 No data is available on the possible effects of lignans in humans. The current theories

- about lignan action in humans have been derived from studies on the effects of diets supplemented with flaxseed products (and thus lignans). Flaxseed in human female diet caused changes in menstrual cycle (Phipps et al. 1993). The subjects, all normally cycling women, showed a longer mean length of luteal phase and higher
- 5 progesterone/17 β -estradiol ration in serum during the luteal phase when they took 10 g of flax seed powder/day in addition to their habitual diets (Phipps et al. 1993). No significant differences between flax and control cycles or concentrations of either estrone or 17 β -estradiol were found. Neither there were any significant differences between flax and control groups for concentrations of serum estrogens in
- 10 postmenopausal women (Brzezinski et al. 1997). Flaxseed supplementation increased SHBG (protein which binds estradiol with high capacity) concentration in serum. This is a typical estrogenic effect in the liver tissue. Increased SHBG concentration on the other hand reduces bioavailability of endogenous estrogens. In healthy young men, the short-term (6 weeks) flaxseed supplementation of the diet (10 g/d in muffins) had no
- 15 significant effect on plasma testosterone concentrations (Shultz et al. 1991) indicating a lack of estrogenicity in the male organism. All together, these studies indicate that lignans may have weak hormonal (estrogenic and antiestrogenic) effects, but the mechanism of their action cannot be fully described by the hormonal effects.
- 20 In conclusion, isolated mammalian lignans have not been available earlier in sufficient amounts to be used in animal experiments or clinical trials, and the only possibility to increase lignan intake has been to increase the consumption of fiber-rich food items such as flaxseed. HMR or any other lignan that is efficiently converted to enterolactone, and can be produced/isolated in large quantities would be valuable in
- 25 the development of pharmaceutical preparations and food products such as functional foods for chemoprevention of cancer and other hormone-related diseases and cardiovascular diseases.

SUMMARY OF THE INVENTION

According to one aspect, this invention concerns a method for prevention of a cancer, a certain non-cancer, hormone dependent disease and/or a cardiovascular disease in a person comprising administering to said person an effective amount of
5 hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.

According to an other aspect, the invention concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum
10 thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person comprising administering to said person an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.

According to a third aspect, the invention concerns a pharmaceutical preparation
15 comprising an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof in combination with a pharmaceutically acceptable carrier.

According to a fourth aspect, the invention concerns a product comprising a liquid or solid material enriched with hydroxymatairesinol or a geometric isomer or a
20 stereoisomer thereof, for use as additive to a food product.

According to a fifth aspect, the invention concerns a food product comprising an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.

25

According to still one aspect, the invention concerns a method for increasing the stability of a food product comprising the addition to said food product of an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the concentration-related inhibition of aromatase by lignans in JEG-3 cells.

5

Figure 2 shows the proliferation of MCF-7 cells in the presence and absence of HMR.

Figure 3 shows the uterine wet weight of immature rats treated with HMR or with an aromatase inhibitor.

10

Figure 4 shows the antitumor activity of HMR against DMBA-induced mammary gland tumors in female rats.

Figure 5 shows the excretion of enterolactone in the urine of rats treated with different
15 doses of HMR.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to the use of a lignan, hydroxymatairesinol (HMR), for the
20 prevention of cancer, non-cancer, hormone dependent diseases and cardiovascular
diseases by adding said HMR into food or by using it as a pharmaceutical preparation.
Surprisingly, HMR is metabolized in vivo to enterolactone, which is assumed to
account at least partly for the antitumor properties of the lignans. Antioxidative
activity of HMR in vitro is strong and this property indicates that HMR can also
25 prevent cardiovascular diseases through the protective effect against damaging free
oxygen species in the body. The invention relates also to the use of HMR as a food
additive to increase the food stability (i.e. inhibit lipid and pigment oxidations and
vitamin losses which cause loss of nutritional value and development of off-flavors in
food).

30

The method according to this invention is particularly effective in the prevention of cancers such as breast cancer, prostate cancer and colon cancer, non-cancer, hormonal dependent diseases such as lower urinary tract symptoms, urethral dyssynergia, bladder instability, bladder outlet obstruction, benign prostatic hyperplasia, and gynecomastia in men, and cardiovascular diseases resulting from oxidized LDL in serum.

The pharmaceutical preparation according to this invention is preferably an oral formulation . The required amount of the active compound (HMR) will vary with the particular condition to be prevented. A typical dose ranges from about 10 to about 100 mg per day and adult person.

In the food additive of the invention, the material to be enriched with hydroxymatairesinol can be any edible, non-toxic solid or liquid material suitable to be admixed with HMR without affecting the properties of HMR. The role of the material is mainly to make the exact dosage of HMR easier. A suitable concentration is for example 100 mg to 1g of HMR per 100 g of enriched material.

The food product according to this invention is especially a functional food, a nutritional supplement, a nutrient, a pharmafood, a nutraceutical, a health food, a designer food or any food product. A suitable concentration of HMR in the food product is, for example, 1 to 20 mg of HMR per 100 g of food product.

The functional food according to this invention can, for example be in the form of butter, margarin, biscuits, bread, cake, candy, confectionery, yogurt or an other fermented milk product, or cereal such as muesli.

The addition of hydroxymatairesinol is particularly useful to increase food stability in the meaning of inhibition of lipid, vitamin and pigment oxidations, which cause loss of nutritional value and development of off-flavors in food. A suitable concentration

of HMR for this purpose is, for example, about 0.1 %.

Isolation of HMR for use in this invention can be made from oversize chip fraction (containing branches, twists and knots) of compression wood and use of HMR in the
5 prevention of diseases such as cancer and cardiovascular diseases.

The properties of HMR were studied by seven different assays:

1. Measurement of antioxidant capacity in vitro
2. Measurement of aromatase inhibiting capacity in JEG-3 cells
- 10 3. Measurement of estrogenic and antiestrogenic activity in MCF-7 cell cultures
4. Evaluation of estrogenic and antiestrogenic activity by uterine growth bioassay
5. Measurement of estrogenic and antiestrogenic activity in adult male rats
6. Investigating the antitumor activity in rat DMBA-induced mammary cancer model
7. Analysis of metabolites from rat urine after different doses of HMR

15

The isolation and purification of HMR in sufficient amounts for biological tests has been impossible earlier because it is a component of wood lignans, which have been relatively poorly characterized. Understanding the distribution of HMR in different parts of spruce (Ekman 1976 and 1979) has given the opportunity to study lignans and
20 especially HMR in detail.

A linear correlation was found between the doses of HMR and the amounts of urinary enterolactone. Enterolactone is a well known mammalian lignan formed by intestinal bacteria from matairesinol or by oxidation of enterodiol (Axelson and Setchell 1981;
25 Axelson et al. 1982). Only minute amounts of unmetabolized HMR and other metabolites (enterodiol and 7-hydroxyenterolactone) were found in urine. Their amounts remained unchanged when the daily dose of HMR was increased. These findings suggest that HMR was metabolized to enterolactone, and, further, enterolactone derived from HMR through demethylation and dehydroxylation steps is
30 not converted to enterodiol. Based on the structure of HMR one had expected that 7-

hydroxyenterolactone were the main metabolite of HMR, but this was not the case. This hydroxyl group is eliminated in the metabolism. The metabolism of HMR differs from that of SDG. SDG is metabolized to enterodiol which is partly oxidized to enterolactone (Rickard et al. 1996; Lampe et al. 1994). HMR thus offers an advantage
5 over SDG as a direct precursor of enterolactone.

HMR had weak if any estrogenic action in rat uterus or in the male organism. It exerted weak but not significant estrogen-like activity in MCF-7 cells. No antiestrogenic activity was demonstrated for HMR. Therefore, it is surprising that it
10 had highly significant antitumor activity in DMBA-induced tumor model in rats as shown in Figure 2. The activity of HMR may be due to HMR itself or to enterolactone. However, no dose-dependence was found in the chemopreventive action of HMR when given in two different doses (3 and 15 mg/kg) to rats after DMBA-treatment. Thus HMR needs not to be converted to enterolactone to have an
15 antitumor effect or smaller doses of these lignans are sufficient to accomplish the maximal chemopreventive effects.

HMR is very effective antioxidant as shown in Tables 2 and 3. It is one of the most potent known inhibitors of lipid peroxidation and excellent inhibitor of LDL
20 oxidation. Inhibition of LDL oxidation is considered to be of special importance in humans as the concentration of oxidized LDL in serum is considered to be one of the best predictors of cardiovascular diseases such as atherosclerosis. HMR may serve as a food additive to increase the food stability (i.e. inhibit vitamin, lipid and pigment oxidations which cause loss of nutritional value and development of off-flavors in
25 food), because HMR was much better superoxide anion scavenging and peroxy radical scavenging agent than well known antioxidants butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT), which are commonly used for increasing the food stability.

EXPERIMENTS

Chemicals

- 5 Various lignans were tested in vitro for their estrogenicity, antiestrogenicity, capability to inhibit aromatization and for their antioxidative properties. The test compounds were purchased from the following sources: enterodiol and enterolactone from Plantech, London, UK, and 7-hydroxyenterolactone containing two 7-OH enantiomers was a generous gift from Dr. Kristina Wähälä, Department of Applied Chemistry,
10 University of Helsinki, Finland.

Extraction of HMR from wood

- HMR extracts were isolated from Norway spruce (*Picea abies*) as described by
15 Ekman, 1976 and Ekman 1979. Shortly, freeze-dried ground heartwood was Soxhlet-extracted in with hexane to remove non-polar lipophilic extractive. The wood sample was re-extracted in the same apparatus with acetone/water (9:1 v/v) to give crude lignans. Hydroxymatairesinol (HMR) and its isomer were isolated and re-chromatographed with XAD-resin for further purification.

20

Measurement of antioxidant capacity in vitro

- The antioxidative capacity of lignans was estimated by four different methods: 1) inhibition of lipid peroxidation, 2) inhibition of low density lipoprotein (LDL)
25 oxidation, 3) superoxide anion scavenging and 4) peroxy radical scavenging assays.

- Inhibition of lipid peroxidation was evaluated on the basis of their potency to inhibit tert-butylhydroperoxide-induced lipid peroxidation (t-BuOOH-LP) in rat liver microsomes in vitro (Ahotupa et al. 1997). The test for the t-BuOOH-LP was carried
30 out as follows: The buffer (50 mM sodium carbonate, pH 10.2, with 0.1 mM EDTA)

was pipetted in a volume of 0.8 ml in the luminometer cuvette. Twenty microliters of diluted liver microsomes, final concentration 1.5 mg protein/ml, was added, followed by 6 ml of luminol (0.5 mg/ml) and test chemicals. The test compounds were added to incubation mixtures in a small volume diluted in ethanol or dimethylsulphoxide (2% of incubation volume), and the lipid peroxidation potency was compared to that of the vehicle (ethanol or dimethyl sulphoxide). The reaction was initiated by 0.05 ml of 0.9 mM t-BuOOH at 33°C. Chemiluminescence was measured for about 45 min at 1 min cycles, and the area under curve (integral) was calculated. Chemiluminescence measurements were carried out using a Bio-Orbit 1251 Luminometer (Bio-Orbit, 10 Turku, Finland) connected to a personal computer using dedicated software for the assays.

Inhibition of LDL oxidation was estimated as described by Ahotupa et al, 1996. Shortly: LDL was isolated by precipitation with buffered heparin. After resuspension in phosphate buffer, 20 mM CuCl₂ was added and the mixture was 15 incubated for 3 hrs at + 37°C. After this, LDL lipids were extracted with chloroform-methanol, dried under nitrogen, redissolved in cyclohexane and analyzed spectrophotometrically at 234 nm. The intensity of absorbance is indicative of LDL oxidation. To test the ability of different compounds to prevent LDL oxidation, the compounds were added to the incubation mixture prior addition of CuCl₂. Possible 20 interference of test compounds with the assay procedure was excluded by measuring the absorption at 234 nm before and after the incubation period. For those compounds which showed antioxidative potency at the starting concentration (0,1 mM), IC-50 values (i.e. concentrations at which test compound inhibited LDL oxidation by 50%) 25 was determined.

Superoxide anion scavenging method was based on the superoxide anion produced in controlled conditions by xanthine-xanthine oxidase system and detection of the generated reactive oxygen species by luminometer (Ahotupa et al., 1997). The ability 30 of test compounds to decrease the chemiluminescence was evaluated. IC-50

concentration (concentration which prevented the chemiluminescence by 50%) was calculated.

5 Peroxyl radiocal scavenging assay was based on generation of peroxyl radicals by thermal decomposition of 2,2'-azobis(2-amidinopropane)HCl and their detection by chemiluminescence (Ahotupa et al., 1997). The results were calculated as the stoichiometric factor, i.e. how many moles of peroxyl radicals can be scavenged by one mole of the test compound.

10 Measurement of aromatase inhibiting capacity in JEG-3 cells

The effects of HMR and structurally related lignans (enterolactone, enterodiols and 7-hydroxyenterolactone) were studied on formation of ^3H -17 β -estradiol from ^3H -androstenedione in JEG-3 cells, human choriocarcinoma cell line. The JEG-3
15 choriocarcinoma cells are a useful aromatase model enabling the study of aromatase inhibition in vitro (Krekels et al 1991). Cells were maintained in DMEM containing 10% fetal calf serum (FCS). The incubation mixture contained 50 μl ^3H -androst-4-ene, 3,17-dione (0.5 nM), 50 μl unlabelled androstenedione (0.5 nM), 100 μl test compounds (10 mM) and 800 μl cell suspension (1 million cells). After the incubation
20 for 4 h, unlabelled carriers (androstenedione, testosterone, 17 β -estradiol and estrone) were added. The steroids were extracted twice with 3.0 ml dichloromethane. HPLC was used for separation and quantification of the radiolabelled ^3H -17 β -estradiol as previously described (Mäkelä et al. 1995). The column system consisted of a guard column followed by a C18 150 x 3.9 mm ID analytical column (Technopak 10 C18
25 HPLC Technology; Wellington House, Cheshire, UK). The mobile phase was acetonitrile /water (35/65) and the flow rate was 1.2 ml/min. For in-line detection of the radioactive metabolites, the eluent of the HPCL column was continuously mixed with liquid scintillant and then monitored with in-line radioactivity detector.

30 Measurement of estrogenic and antiestrogenic activity in MCF-7 cell cultures

The MCF-7 cell line (human breast cancer cells) stock cultures were grown in phenol red free RPMI medium supplemented with 5 % FCS, 100 U/ml penicillin and 100 µg/ml streptomycin, 10 µg/ml insulin and 1 nM 17β-estradiol in T-75 cell culture bottles. The medium was replaced with fresh ones three times per week. The stock cultures were harvested by trypsinization and suspended in 10 ml phenol red free versene solution and centrifuged for 5 min 800 rpm. The cell pellet was carefully resuspended into RPMI medium supplemented with 5 % dextran charcoal stripped FCS (dcFCS) and seeded on 6 well plates 50 000 cells/ 3.0 ml medium/ well. On the second day of culture the medium was changed and test compounds were added. To test the estrogenicity of the lignan compounds, they were diluted in ethanol and added to cell cultures in final concentration of 1.0 M. In each proliferation assay 1.0 nM 17β-estradiol solution in ethanol was used as a positive control for estrogenic response. Equal amounts of ethanol were added to control wells. To test the antiestrogenicity both 17β-estradiol and lignan solutions were added to cell cultures. The cells were cultured for 5 to 7 days in the presence of test compounds, and the medium was changed every second day. Cell proliferation was quantified by counting the released nuclei with Coulter counter.

Evaluation of estrogenic and antiestrogenic activity in immature rat uterotrophic test

The estrogenicity HMR was evaluated by the uterotrophic assay in immature rats which was performed as described earlier (Jordan et al. 1977), with the exception of treatment time which was 7 days instead of 3 days in the reference study. The treatment time was longer because of the expected weak estrogenicity of the test compound. The treatment of immature rats with an aromatase inhibitor (MPV-2213ad), which prevents biosynthesis of estradiol, was used as a methodological control for non-estrogen-stimulated uterus.

Evaluation of estrogenic and antiestrogenic activity in adult male rats

Estrogenic (antiandrogenic) and antiestrogenic effects of HMR were studied in intact and hypoandrogenic Noble strain male rats (age 6 – 9 month), correspondingly. The
5 chronic hypoandrogenic state with both structural and functional changes in the male reproductive tract was induced by neonatal estrogenization (diethylstilbestrol, 10.0 µg/kg body weight in rape oil s.c. on postnatal days 1-5). These changes are known to be partly reversible by aromatase inhibitor treatment consisting daily dose of MPV-2213 ad 10-30 mg/kg body weight (Streng et al. unpublished observations).

10

Animals were fed the soy-free basal diet (SDS, Whitham Essex, England) and they had a free access to water. Twelve of both intact and hypoandrogenic animals were cavaged in daily dosage of HMR 50 mg/kg body weight in rape oil. Another twelve
15 animals from both animal models were cavaged with rape oil only as a placebo treatment. After four-week treatment the animals were sacrificed. The weights of testis and accessory sex glands (ventral prostate, seminal vesicles and coagulating gland) were measured. Serum and testis testosterone and pituitary and serum luteinizing hormone (LH) levels were measured by immunoassays (Haavisto et al. 1993).

20 Investigating the antitumor activity in rat DMBA-induced mammary cancer model

Antitumor activity of HMR in rat mammary cancer was studied as described earlier (Kangas et al. 1986). Fifty-day-old female Sprague-Dawley rats were given 12.0 mg DMBA (dimethylbentz[a]anthracene) by cavage. After approximately 6 weeks
25 palpable tumors could be detected, whereafter the width (w) and the length (l) of the tumors were measured once a week to determine the tumor volumes according to a formula $V = (\pi w^2 l)/12$. The rats were also weighed once a week. The rats were allocated in 3 different groups so that the total number of tumors in the beginning of the experiment was similar in each group: (1) Control group 8 animals, (2) HMR 3.0
30 mg/kg 7 animals, and (3) HMR 15.0 mg/kg 7 animals, one of which had to be killed

before the end of the experiment.

HMR was given per os starting 9 weeks after the DMBA-induction, i.e. 3 weeks after palpable tumors appeared, and was given daily for 7.5 weeks. At the end of the experiment the tumors were classified in groups according to their growth pattern: 1.

- 5 Growing tumors (PD = progressive disease); 2. Non-growing, stabilized tumors (SD = stabilized disease, no change in tumor volume or regression less than 75%); 3. Regressing tumors (PR = partial response, regression of tumor volume more than 75%); 4. Disappeared tumors (CR = complete response, no palpable tumor).

10 Analysis of metabolites from rat urine receiving different doses of HMR

Ten Sprague – Dawley male rats (age 4 month) were used to study the metabolism of HMR in vivo. Animals were housed in pairs with 12 h light:dark cycle and had free access to water and soy-free basal diet (SDS, Whitham Essex, England) during the
15 metabolism study.

Rats were gavaged with HMR dissolved in 10 % ethanol in PEG in doses 3, 15, 25 and 50 mg/kg body weight once a day for two days. After second gavaging the 24 hour urine was collected in metabolic cages in collection jars containing 120 µl 0,56 M
20 ascorbic acid and 120 µl 0,15 M Na-azide as preservatives. The centrifuged urine volumes were measured and stored in -20°C. For pretreatment 750 µl 0.2 M acetate buffer (pH 4.0 ± 0.1) was added to 3.0 ml thawed urine aliquots. Sep-Pak C18 columns (100 mg silica based resin/column) were used for urine extractions. Columns were preconditioned with 3.0 ml H₂O, 3.0 ml methanol and 3.0 ml acetate buffer.
25 After urine had filtered through the column and washed with 3.0 ml of acetate buffer polyphenolics were eluted with 3.0 ml methanol. The eluate was evaporated to dryness under nitrogen in +45°C water bath and dried residues were redissolved in 3.0 ml of 0.2 M acetate buffer. 30 µl Helix pomatia enzyme mix was added and the solutions were incubated in +37°C to hydrolyze both glucuronides and sulfates. 300 µl of
30 flavone stock solution (100 µg/ml in EtOH) was added into hydrolyzed samples. The

samples were extracted in C-18 columns and evaporated to dryness as described above and stored in -20°C until analyzed with GC-MS.

The evaporated urine samples were dissolved in pyridine, and silylated by adding
5 BSTFA:TMCS (10:1) silylation reagent. The GC-MS analyses of the silylated samples were performed with an HP 6890-5973 GC-MS instrument. The GC column was an HP-1 crosslinked methyl polysiloxane column (15 m x 0,25 mm i.d., 0,25 µm film thickness). Helium was used as carrier gas at a flow of 1 ml/min. The GC-oven was temperature programmed from 60°C to 290°C, at 8°C/min heating rate. The GC-
10 injector was set in split-mode at a split ratio of 1:15. The injector temperature was 250°C. Compound identifications were based on mass spectra. The quantitative calculations were based on uncorrected peak areas of target components relative to the internal standard.

15 RESULTS

Assessment of antioxidant capacity in vitro

HMR had stronger lipid peroxidation capacity than any other lignan or flavonoid in
20 our tests (Table 2). HMR was compared to well known antioxidants TROLOX, which is a water soluble vitamin E derivative, and BHA and BHT in the ability of inhibiting lipid peroxidation, inhibition of LDL oxidation, and scavenging superoxide and peroxy radicals (Table 3). HMR was as a whole the strongest antioxidant, more effective than BHA or BHT in all assays, and stronger than TROLOX in all assays
25 except for lipid peroxidation inhibition assay, where the compounds were almost equally active.

Aromatase inhibiting capacity in JEG-3 cells

30 The inhibition of ³H-17β-estradiol formation from ³H-androstenedione in JEG-3 cells

was tested at different concentrations of HMR. The inhibitory capacity of HMR was compared to enterolactone, 7-hydroxyenterolactone and enterodiol. Enterolactone caused a dose-dependent inhibition of aromatization within the concentration range of 1.0 to 10.0 μ M. It was further shown that enterodiol was noninhibitory indicating that the lactone ring is critical for the inhibition. 7-hydroxyenterolactone and hydroxymatairesinol had no inhibitory effects (Figure 1) indicating the importance of the number and location hydroxyl groups in the lignan molecule for the aromatase inhibition.

10 Estrogenic and antiestrogenic activity in MCF-7 cell cultures

HMR had very weak, not statistically significant estrogenic or antiestrogenic activity in MCF-7 cell proliferation assays as shown in Figure 2.

15 Evaluation of estrogenic and antiestrogenic activity in immature rat uterotrophic test

Figure 3 illustrates the effects of HMR on the uterine growth of the immature rats. HMR had no significant estrogenic effect on the uterine weight gain of the immature rats. Neither did HMR reduce the weight gains indicating no antiestrogenic effect.

20 Aromatase inhibitor prevented the increase of uterine weight, as expected, indicating that the method for the measurement of the aromatase inhibitors was adequate.

Evaluation of estrogenic and antiestrogenic activity in adult male rats

25 After a 4-week treatment with HMR, no significant changes in the weights of accessory sex glands and testis were observed in control and hypoandrogenic animals (Table 4). There were no significant changes in testosterone or LH concentrations, either (Table 5). These results indicate, that HMR is not a full estrogen agonist in male organism, because it does not exert the typical estrogenic activity on hypothalamus - hypophysis - gonad - axis (inhibition of LH and androgen secretion). Neither is HMR

30

an antiestrogen because it does not reverse the changes induced by neonatal estrogenization in the male rat.

Investigating the antitumor activity in rat DMBA induced mammary cancer model

5

Number of growing (PD) versus stable (SD) tumors, regressing (PR) tumors and disappeared (CR) tumors is presented in Figure 4. The antitumor effect of HMR was found to be statistically very significant. There was no clear dose-dependency of antitumor action in this model. Both antioxidative and tumor growth regressing
10 properties of HMR may therefore be connected with the in vivo antitumor activity. The mechanism of antitumor activity of HMR in vivo is still unknown.

Analysis of metabolites from rat urine after different doses of HMR

15 Figure 5 illustrates that the main excreting metabolite of HMR in rats is enterolactone, which may be the biologically active compound. This is surprising taking into account the chemical structure of HMR, because one would expect hydroxyenterolactone to be the main metabolite. The metabolism of HMR to enterolactone may be catalyzed by bacterial intestinal flora rather than by the rat liver.

20

CONCLUSIONS

Hydroxymatairesinol (HMR) has antitumor activity either as unchanged compound and/or after conversion to enterolactone in DMBA induced breast cancer model. HMR
25 has therefore a potential to have beneficial effects in humans who are at risk of developing breast cancer (BC), prostate cancer (PC), colon cancer or benign prostatic hyperplasia (BPH). HMR is metabolized to enterolactone which inhibits aromatization in vitro. HMR may as a precursor of aromatase inhibitor also prevent the development of lower urinary tract symptoms (LUTS), bladder instability, bladder outlet
30 obstruction, urethral dyssynergia, and gynecomastia. HMR has also strong

antioxidative activity and may therefore be used as food additive (antioxidant). HMR as pharmaceutical product or dietary supplement may have advantageous cardiovascular effects in humans. Addition of HMR to food to make innovative new functional food, nutraceutical, health food, pharmafood, designer food or novel food is
5 feasible.

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not
10 depart from the spirit of the invention. Thus, the described embodiments are illustrative and should not be construed as restrictive.

Table 1.

Production of mammalian lignans from different plant food by *in vitro* fermentation with human fecal flora.

	$\mu\text{g}/100\text{ g}$
FLAXSEED FLOUR	68 000
SOYBEAN	170
CEREAL BRANS:	
WHEAT	570
OAT	650
WHOLE CEREALS:	
RYE	160
POTATO	80
CARROT	350
ONION	110

¹Thompson et al. Nutrition and Cancer 16:43-52, 1991

Table 2.

ANTIOXIDANT PROPERTIES OF LIGNANS AND SOME RELATED FLAVONOIDS *IN VITRO*
BY LIPID PEROXIDATION INHIBITION TEST.

Compound	Antioxidative capacity (t-BuOOH-LP) IC ₅₀ (μM)
Flav noids	
kaempferol (3,4',5,7-tetrahydroxy- flavone)	0.9
quercetin (3,3',4',5,7-pentahydroxy- flavone)	0.4
kaempferide (3,5,7-trihydroxy-4'-methoxy- flavone)	0.5
Lignans	
enterolactone 2,3-bis-(3'-hydroxybenzyl)-butyrolactone	15.9
enterodiol 2,3-bis-(3'-hydroxybenzyl)-butane-1,4-diol	12.7
hydroxymatairesinol	0.08

Table 3.

COMPARISON OF ANTIOXIDATIVE EFFECTS OF HMR AND KNOWN ANTIOXIDANTS IN VITRO. IC-50 concentrations have been presented, except for peroxy radical scavenging assay where the stoichiometric factor (i.e. how many moles of peroxy radical one mole of test compound can scavenge) .

	HMR ¹	TROLOX ²	BHA ³	BHT ⁴
Inhibition of lipid peroxidation	0,06 µM	0,02 µM	1,1 µM	15,3 µM
Inhibition of LDL oxidation	2,0 µM	2,7 µM	not determined	
Superoxide anion scavenging	5,6 µM	25 µM	15 µM	> 1 mM
Peroxy radical scavenging	1 : 4	1 : 2	not determined	

¹ hydroxymatairesinol

² water soluble E-vitamin derivative

³ Butylated hydroxyanisol (synthetic antioxidant)

⁴ Butylated hydroxytoluene (synthetic antioxidant)

Determination methods have been described in the text.

Table 4.

The effect of four week exposure to HMR on male rat reproductive organ relative weights¹

	Treatment	n	Body weight	Testis	Ventral Prostate	Seminal vesicle	Coaculating gland
			g	mg/kg body weight			
Intact animals	Placebo	12	426 ± 28	4362 ± 170	909 ± 146	412 ± 43	223 ± 49
	HMR 50 mg/kg	12	447 ± 38	4223 ± 304	938 ± 148	419 ± 59	204 ± 48
Hypoandrogenic animals	Placebo	12	481 ± 29	3340 ± 509	333 ± 188	249 ± 63	69 ± 49
	HMR 50 mg/kg	12	455 ± 36	3276 ± 327	378 ± 198	266 ± 49	70 ± 30

¹ Data is expressed as mean ± SD (mg/kg body weight). Relative weights after HMR treatment are not significantly different from placebo in either group.

Table 5.

The effect of four week exposure to HMR on male rat testosterone and LH concentrations¹

	Treatment	n	Testis testosterone (ng/testis)	Serum testosterone (ng/ml)	Pituitary LH (µg/pit)	Serum LH (ng/ml)
Intact animals	Placebo	12	97,6 ± 46,3	2,405 ± 1,122	6,747 ± 2,479	1,804 ± 1,294
	50 mg/kg HMR	12	112,9 ± 58,5	2,770 ± 1,421	6,838 ± 2,061	1,088 ± 0,352
Hypoandrogenic animals	Placebo	12	63,5 ± 25,9	1,197 ± 0,663	8,673 ± 2,224	0,712 ± 0,371
	50 mg/kg HMR	12	48,0 ± 15,2	0,939 ± 0,431	7,530 ± 2,286	0,854 ± 0,333

¹ Data is expressed as mean ± SD. Hormone concentrations after HMR treatment are not significantly different from placebo in either group.

REFERENCES

- Adlercreutz H, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T, Arosemena PJ, Kellis JT, and Vickery LE: Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. *J Steroid Biochem Mol Biol*, 44: 147-153, 1993.
- Ahotupa M, Ruutu M, and Mäntylä E: Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. *Clin Biochem*, 29: 139-144, 1996.
- Ahotupa M, Mäntylä E, and Kangas L: Antioxidant properties of the triphenylethylene antiestrogen drug toremifene. *Naunyn-Schmiedeberg's Arch Pharmacol*, 356: 297-302, 1997.
- Axelsson M and Setchell KDR: The excretion of lignans in rats - evidence for an intestinal bacterial source for this new group of compounds. *FEBS Lett*, 123: 337-342, 1981.
- Axelsson M, Sjövall J, Gustafsson BE and Setchell KDR: Origin of lignans in mammals and identification of a precursor from plants. *Nature*, 298: 659-660, 1982.
- Ayres D, and Loike, J. Lignans: Chemical, biological and clinical properties. Cambridge university press, 1990.
- Brzezinski A, Adlercreutz H, Shaoul R, Rösler A, Shmueli A, Tanos V and Schenker JG: Short-term effects of phytoestrogen-rich diet on postmenopausal women. *Menopause (The Journal of the North American Menopause Society)*, 4: 89-94, 1997.
- Ekman R: Analysis of lignans in Norway spruce by combined gas chromatography-mass spectrometry. *Holzforschung*, 30:79-85, 1976.

Ekman R: Distribution of lignans in Norway spruce. *Acta Academiae Aboensis, Ser B*, 39:1-6, 1979.

- 5 Evans BA, Griffiths K and Morton MS. Inhibition of 5 α -reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. *J Endocrinol*, 147: 295-302, 1995.

- Haavisto A-M, Petterson K, Bergendahl M, Perheentupa A, Roser JF, and Huhtaniemi
10 I A. Supersensitive immunofluorometric assay for rat luteinizing hormone. *Endocrinology*, 132: 1687-1691, 1993.

- Hultén K, Adlercreutz H, Winkvist A, Lenner P, Hallmans G and Ågren Å. Low
levels of phyto-estrogens in blood as risk factor for breast cancer. In: COST 916
15 Workshop 'Phyto-oestrogens: exposure, bioavailability, health benefits and safety concerns', 1998

Ingram D, Sanders K, Kolybaba M and Lopez D. Case-control study of phyto-
oestrogens and breast cancer. *Lancet*, Oct 4;350(9083): 990-994, 1997.

20

Jenab M and Thompson LU. The influence of flaxseed and lignans on colon
carcinogenesis and beta-glucuronidase activity. *Carcinogenesis*, Jun;17(6):1343-1348,
1996

- 25 Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antiestrogenic activity. *J Endocrinol*, 75: 305-316, 1977.

- Kangas L, Nieminen A-L, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M,
Södervall M and Toivola R: A new triphenylethylene compound, Fc-1157a. II
30 Antitumor effects. *Cancer Chemother Pharmacol*, 17:109-113, 1986.

Lampe JW, Martini MC, Kurzer MS, Adlercreutz H and Slavin JL: Urinary lignan and isoflavonoid excretion in premenopausal women consuming flaxseed powder. *Am J Clin Nutr*, 60:122-8, 1994.

5

Landstrom M, Zhang JX, Hallmans G, Aman P, Bergh A, Damber JE, Mazur W, Wähälä K and Adlercreutz H. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostateadenocarcinoma in rats. *Prostate*, Aug 1; 36(3): 151-161, 1998

10

Mousavi Y and Adlercreutz H: Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. *J Steroid Biochem Mol Biol*, 41: 615-619, 1992.

15

Mattinen J, Sjöholm R and Ekman R. NMR-spectroscopic study of hydroxymatairesinol, the major lignan in Norway spruce (*Picea abies*) heartwood. *ACH models in chemistry*, 135(4):583-590, 1998.

20

Mäkelä S, Poutanen M, Lehtimäki J, Kostian M-L, Santti R and Vihko R. Estrogen-specific 17 β -hydroxysteroid oxidoreductase type 1 (E.C.1.1.1.62) as a possible target for the action of phytoestrogens. *P.S.E.B.M.*, 208:51-59, 1995.

Phipps WR, Martini MC, Lampe JW, Slavin JL and Kurzer MS. Effect of flax seed ingestion on the menstrual cycle. *J Clin Endocrinol Metab*, 77(5):1215-1219, 1993.

25

Rickard SE, Orcheson LJ, Seidl MM, Luyengi L, Fong HHS and Thompson LU: Dose-dependent production of mammalian lignans in rats and in vitro from the purified precursor secoisolariciresinol diglycoside in flaxseed. *J Nutr*, 126: 2012-2019, 1996.

30

Shultz TD, Bonorden WR and Seaman WR. Effect of short-time flaxseed consumption on lignan and sex hormone metabolism in men. *Nutrition Research*, 11:1089-110, 1991.

- 5 Serraino M and Thompson LU: The effect of flaxseed supplementation on early risk markers for mammary carcinogenesis. *Cancer Letters*, 60: 135-142, 1991.

Serraino M and Thompson LU: The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis. *Nutr Cancer*, 17:153-
10 159, 1992.

Setchell KDR, Borriello SP, Gordon H, Lawson AM, Harkness R and Morgan DML. Lignan formation in man – microbial involvement and possible roles in relation to cancer. *Lancet*, 4:4-7, 1981

15

Streng T, Talo A and Santti R. Unpublished observations.

Thompson LU, Robb P, Serraino M and Cheung F. Mammalian lignan production from various foods. *Nutr Cancer*, 16: 43-52, 1991

20

Thompson LU, Seidl MM, Rickard SE, Orcheson LJ, and Fong HHS: Antitumorigenic effect of a mammalian lignan precursors from flaxseed. *Nutr Cancer*, 26: 159-165, 1996a.

- 25 Thompson LU, Rickard SE, Orcheson LJ and Seidl MM: Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. *Carcinogenesis*, 17: 1373-1376, 1996b.

Tou JCL, Chen J and Thompson U. Flaxseed and its lignan precursor, secoisolariciresinol diglycoside, affect pregnancy outcome and reproductive
30

development in rats. J Nutr, 128: 1861-1868, 1998.

Wang C, Mäkelä T, Hase T, Adlercreutz H and Kurzer MS: Lignans and flavonoids inhibit aromatase enzyme in human adipocytes. J Steroid Biochem Molec Biol, 50:
5 205-212, 1994.

Waters AP and Knowler JT. Effect of a lignan (HPMF) on RNA synthesis in the rat uterus. J Reprod. Fert, 66:379-381, 1982.

10 Zhang J-X, Hallmans G, Landström M, Bergh A, Damber J-E, Åman P and Adlercreutz H. soy and rye diets inhibit the development of Dunning R3327 prostatic adenocarcinoma in rats. Cancer Letters, 114: 313-314, 1997.

CLAIMS

1. A method for prevention of a cancer, a certain non-cancer, hormone dependent disease and/or a cardiovascular disease in a person comprising administering to said
5 person an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.
2. The method according to claim 1 wherein said cancer is selected from the group consisting of breast cancer, prostate cancer and colon cancer.
- 10 3. The method according to claim 1 wherein said non-cancer, hormonal dependent disease is selected from the group consisting of lower urinary tract symptoms, urethral dyssynergia, bladder instability, bladder outlet obstruction, benign prostatic hyperplasia, and gynecomastia in men.
- 15 4. The method according to claim 1 wherein said cardiovascular disease is resulted from oxidized LDL in serum.
5. A method for increasing the level of enterolactone or another metabolite of
20 hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person comprising administering to said person an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.
- 25 6. The method according to claim 5 wherein said cancer is selected from the group consisting of breast cancer, prostate cancer and colon cancer.
7. The method according to claim 5 wherein said non-cancer, hormonal dependent disease is selected from the group consisting of lower urinary tract symptoms, urethral
30 dyssynergia, benign prostatic hyperplasia, and gynecomastia in men.

8. A pharmaceutical preparation comprising an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof in combination with a pharmaceutically acceptable carrier.
- 5
9. A product comprising a liquid or solid material enriched with hydroxymatairesinol or a geometric isomer or a stereoisomer thereof , for use as additive to a food product.
10. The product according to claim 9 , wherein said food product is selected from the group consisting of a functional food, a nutritional supplement, a nutrient, a pharmafood, a nutraceutical, a health food, a designer food or any food product.
- 10
11. The product according to claim 9 , wherein said food product is a functional food in the form of butter, margarin, biscuits, bread, cake, candy, confectionery, yogurt or an other fermented milk product, or cereal such as muesli.
- 15
12. A food product comprising an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.
13. The food product according to claim 12 wherein said food product is selected from the group consisting of a functional food, a nutritional supplement, a nutrient, a pharmafood, a nutraceutical, a health food, a designer food or any food product.
- 20
14. The food product according to claim 13 , wherein said food product is a functional food in the form of butter, margarin, biscuits, bread, cake, candy, confectionery, yogurt or an other fermented milk product, or cereal such as muesli.
- 25
15. A method for increasing the stability of a food product comprising the addition to said food product of an effective amount of hydroxymatairesinol or a geometric isomer or a stereoisomer thereof.
- 30

16. The method according to claim 15 where the increasing of food stability comprises the inhibition of lipid, vitamin and pigment oxidations, which cause loss of nutritional value and development of off-flavors in food.




FIG. 1

Estrogenic and antiestrogenic activity of HMR in MCF-7 cells. The cell proliferation of control is adjusted to 100 %.

Number of experiments, n = 3-4.

- * Significantly different from control
- A = control (vehicle without hormones)
B = vehicle + estradiol 10^{-9} M
C = vehicle + HMR 10^{-6} M
D = vehicle + HMR 10^{-6} M + estradiol 10^{-9} M




FIG. 2

3/5

Relative uterus weight (mg/kg body weight) of immature rats treated with HMR or MPV-2213ad.

* Significantly different from control




FIG. 3

4/5




FIG. 4

1000

5/5

Urine lignans after different doses of HMR¹

¹ Values are expressed as means with SD bars.
Number of animals per treatment group. n = 2, except in control, n = 1.




FIG. 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 00/00181

A. CLASSIFICATION OF SUBJECT MATTER		
IPC7: C07K 307/32, A61K 31/00, A23L 1/30 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC7: C07D, A61K, A23L		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,X	Chemical Abstracts, vol. 132, 2000, (Columbus, Ohio, USA), Kadoya Seiyu K. K.: "Antioxidants obtained from sesame seeds for pharmaceutical products and food additives", abstract no. 310001, & JP,A2,2000129256, 20000509 --	1-16
X	Plant Polyphenols 2: Chemistry, Biology, Pharmacology, Ecology, Edited by Gross et al. Kluwer Academic/Plenum Publishers, New York, 1999, Joshua D. Ford et al: "Plant ligands and Health: Cancer chemoprevention and biotechnological opportunities", page 675 - page 694 --	1-16
A	WO 9714670 A1 (KANOLDT ARZNEIMITTEL GMBH), 24 April 1997 (24.04.97) --	1-8
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
14 July 2000		21-07-2000
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Carl-Olof Gustafsson/EÖ Telephone No. +46 8 782 25 00

1000

INTERNATIONAL SEARCH REPORT

International application No.
PCT/FI00/00181

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-7
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-7 relate to method for treatment of the human or animal body, a search has been carried out. The search has been based on the alleged effect of the claimed compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).:

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

